Recent evidence for a significant interference of microcrystalline hydroxapatite (HAP) 36 particles with re-and demineralisation processes at the tooth-biofilm interface sug-37 gested, that they may be promising candidates for efficacious caries prevention. 38
Introduction 60
In recent years findings, mostly derived from in vitro studies, suggested, that micro-61 crystalline hydroxyapatite (HAP) particles may be promising candidates for the 62 prevention of cariogenic demineralization and the stimulation of remineralization 63 processes on enamel and dentine surfaces [1] [2] [3] . Huang et al. (2011) reported a 64 regain of mineral content and an increase in microhardness on demineralized bovine 65 enamel slabs that had subsequently been exposed to microcrystalline HAP particles 66 where enamel dissolution usually is initiated [4] . In an in situ -study the use of a zinc-71 carbonate HAP microcluster-containing mouth rinse significantly reduced bacterial 72 colonization on bovine enamel slabs worn intraorally by healthy volunteers [5] . 73 Hannig and Hannig (2010) put these in situ and in vitro findings into a more compre-74 hensive perspective by stating that already physiological tooth wear constantly 75 releases HAP particles into the oral environment, which may subsequently interfere 76 with de-and remineralisation processes as well as with the metabolism of the oral 77 microbiota at the tooth-bacterial biofilm interface [6] . The impact of microcrystalline 78 HAP as an ingredient of dentifrices has been positively evaluated in controlled clinical 79 trials regarding dentinal hypersensitivity [7-10] and parameters of periodontal health 80 [11] . Up to date, however, comparable data regarding the caries-preventive 81
properties of HAP toothpastes are mostly missing. They are limited to positive 82 findings from in situ studies on extracted teeth or standardized enamel and dentine 83 specimen, being subjected to different toothpaste slurries and worn in between by 84 volunteers in intraoral appliances [12] [13] [14] [15] . As orthodontic therapy with fixed 85 appliances is known to be associated with an increased incidence of the overgrowth 86 of a caries-promoting microbiota [16] and the development of white spot enamel 87 caries lesions [17] [18] [19] , this study aimed at the assessment of the caries-preventive 88 impact of the regular use of a fluoride-free HAP dentifrice in this particular group of 89 caries risk patients. Due to the abundant evidence for the caries preventive efficacy 90 of fluorides [20, 21] , clinical caries studies may no longer involve a true negative 91 control for obvious ethical reasons. Thus a non-inferiority trial was conducted. The 92 study hypothesis to be tested was, that, in terms of caries prevention, the regular use 93 of the HAP test dentifrice is not inferior to the regular use of a fluoridated control with 94 proven efficacy. 95 96 Material and methods 97 The investigation was designed as a multicenter, prospective, parallel group, two 98 arm, double-blind, randomized clinical non-inferiority trial to be performed at the 99 German study centers Wuerzburg (leading study center), Regensburg, Munich, 100
Dresden and Frankfurt. The study protocol was prepared in accordance with the 101 declaration of Helsinki and met the criteria of GCP. It was approved by the ethics 102 committee of the University of Wuerzburg (file #184/13) on March 28 th , 2013. 103
Registering clinical trials was not yet generally regarded a mandatory prerequisit to 104 be performed prior to study initiation in 2012 and 2013 during the planning phase of 105 this investigation. Therefore, registration with ClinicalTrials.gov (identifier: At visit 1 (-4 to -28 days prior to baseline) patients scheduled for orthodontic therapy 115
were screened for study eligibility. Those meeting it and giving informed consent 116 were subsequently scheduled for the baseline visit 2 (day 0). 117
At visit 2 Plaque Index (PlI) as well as Gingival Index (GI) scores were recorded from 118 the vestibular surfaces of teeth 15 to 25 followed by professional tooth cleaning and 119 the subsequent assessment of the vestibular enamel surfaces of teeth 15 to 25 120 according to ICDAS II criteria. Afterwards orthodontic brackets were adhesively 121 mounted to the vestibular surfaces and any excess of adhesive resin was removed. 122
No sealants, fluoride varnishes or any other caries-preventive layers surrounding the 123 brackets were applied. Using a randomization list a supply of either the test dentifrice 124 or the control dentifrice, calculated to be adequate for 4 weeks of 2 x daily repeated 125 toothbrushing, as well as a standardized electric tooth brush (Oral-B Pulsar 35; 126
Procter & Gamble GmbH, Germany) to be used for the duration of the study, were 127 handed over to the study patients. The dosage of the assigned dentifrice (2 x daily a 128 streak of approx. 1 g) and the use of the electric tooth brush were practically 129 instructed and the patients informed, to bring back all assigned toothpaste tubes at 130 the cleaning/disinfection procedures as well as the return/handing over of the 136 toothpaste supply performed as described before. At day 84 (visit 5) the recording of 137 GI, PlI and ICDAS II scores as well as cleaning and disinfection were repeated as 138 described before. Next to a new supply of toothpaste also a new Pulsar 35 electric 139 toothbrush was handed over. At day 112 (visit 6) and at day 140 (visit 7) procedures 140 performed were identical to those at day 56 (visit 4). At day 168 (visit 8) the final 141 assessment of PlI, GI and ICDAS II scores as well as the return of the study 142 dentifrices was conducted as described before. Furthermore, at each study visit 143
patients were asked about the occurrence of important harms or unintended effects 144 related or unrelated to the use of the study dentifrices. premolars, canines and incisors with surface integrities ICDAS codes 0-3. 50% of 210 the pictures of a given sample were randomly presented in duplicates to evaluate the 211 ability of the examiners to reproduce their own assessments. 212
Interrater reliability analysis revealed a mean weighted kappa = 0.75 for the first 213 assessment run, which increased to kappa = 0.80 for the final calibration, indicating 214 "substantial agreement" among the different examiners throughout the study [25] . streptococci was extrapolated to be p=80% for the control group using the fluoridated 234 toothpaste. The difference between both experimental groups not be regarded 235 clinically relevant was set to Δ ≤ 20%. A sample size of 2 x 74 study patients was 236 calculated to be sufficient to reject the null hypothesis, that the test dentifrice is 237 inferior to the control dentifrice, using a non-inferiority margin of Δ = 20% for the 238 primary outcome measure and one-sided, exact Fisher Test (α = 5%, power = 80%). 239 240 Blinding, randomisation 241 The trial was designed to blind study patients and examiners to the group assign-242 ment. For this purpose, both study dentifrices (test/control) were filled into neutral 243 plastic tubes of identical shape and color by an independent, GMP certified 244 laboratory for cosmetics. Using block randomization with a block size of 4 a random 245 list was generated to code-label test and control tubes with consecutive unique 246 identification numbers. Randomization of dentifrice assignment was stratified by 247 study center. Handing out of the experimental dentifrices to the study patients 248 followed the sequence of the identification numbers and was performed by trained 249 study nurses not involved in the examination of the study participants. To maintain 250 blinding of examiners and study patients, the study patients were instructed not to 251 discuss toothpaste-related issues with the examiners but with the study nurses only, 252 who were also responsible for instructing the patients in efficacious oral hygiene and 253 taking back the empty or unused dentifrice tubes at the subsequent visits. The 254 number of study nurses varied between a minimum of one and a maximum of four 255 per study center. 256 257 Statistical analysis 258 The primary outcome measure was analysed primarily for the PP population and 259 repeated for sensitivity reasons, for the ITT population. The exact confidence limits 260 (Clopper-Pearson) were computed to test non-inferiority (cp. [28] ). For the primary 261 outcome measure, non-inferiority was claimed, if the upper limit of the one-sided 95% 262 confidence for the corresponding difference between test and control dentifrice was 263 less than Δ ≤ 20%. 264
In addition, two-sided Wilcoxon-Mann-Whitney tests were used for between group Six patients of the test group and 4 patients of the control group terminated study 284 participation prematurely due to lack of interest or not keeping the follow-up appoint-285 ments. Further 6 patients completed the study but were excluded from the PP 286 analysis due to insufficient dosing of the assigned dentifrice, calculated from the 287 residual weight of the returned dentifrice tubes. All but one patient of the test group 288 and all patients of the control group received at least one dose of the assigned 289 dentifrice (n=149) and were thus primarily included in the ITT analysis set. As two 290 study patients left the trial already before the first reevaluation at week 4, the total 291 number of study individuals suitable for an inclusion in the ITT analysis of caries 292 development further decreased to n=147. No important harms or unintended effects 293 related or unrelated to the use of the study dentifrices were reported. Finally, a total 294 of 133 study patients (64 test / 69 control) was included in the PP analysis set (Fig 2) . Blinded change of the primary outcome 305 A blinded analysis of the ICDAS data at the end of the study revealed, that the 306 overall observed occurrence of ICDAS lesions ≥ code 2 in the study population was 307 29.3% and therefore considerably lower than the anticipated value (p = 80%) used 308 for the sample size calculation. As the difference between the groups not be 309 regarded clinically relevant had been set in the study protocol to ∆ ≤ 20% a clinically 310 meaningful verification of non-inferiority was no longer warranted. Thus, the primary 311 endpoint was changed to the more frequent overall occurrence of ICDAS lesions 
Non-inferiority analysis
338 Table 2 displays the difference between both experimental groups regarding the 339 percentage of study subjects experiencing the new occurrence of at least one ICDAS 340 lesion ≥ code 1 (primary outcome) or at least one ICDAS lesion ≥ code 2 (secondary 341 outcome) including the corresponding one-sided 95% confidence intervals. As the 342 upper limits of the 95% confidence intervals for the primary outcome are well below 343 the given non-inferiority margin of ∆ ≤ 20% for both analysis sets (PP: 8%; ITT: 9%) 344
the HAP group has to be considered as non-inferior to the fluoride control. 345
Also regarding the secondary outcome (ICDAS lesion ≥ code 2) the upper limits of 346 the 95% confidence intervals are substantially below the given non-inferiority margin 347 of 20% for both analysis sets (PP: 3%, ITT: 7%), indicating that again the HAP test 348 group has to be considered being non-inferior to the fluoridated control. 
Effect of study site on the primary outcome measure 360
The effect of study site on the primary outcome measure ΔICDAS score ≥ 1 at week 361 24 was evaluated by logistic regression analysis. It included the factors study site, 362 treatment group and the interaction between study site and treatment group. Due to 363 small sample sizes, the data for the study sites Dresden, Munich and Frankfurt were 364 pooled (n=40 patients). The results revealed a significantly lower incidence of the 365 primary outcome at week 24 (p<0.001) at the combined smaller centers (Dresden, 366
Munich, Frankfurt) when compared to the study centers in Regensburg (n=72 367 patients) or Wuerzburg (n=35 patients). However, there was no significant interaction 368 between study site and treatment group, proving that the factor study site did not 369 significantly affect efficacy differences between the treatment groups (for further 370 informations see also Appendix 1) . 371 372 Number and severity of ICDAS score increases 373 374
The number and severity of ICDAS score increases on the vestibular surfaces of 375 teeth 15-25 over the course of the study are shown in Caries detection and grading in this trial followed the principles of ICDAS-II [23], an 409 internationally established, state of the art caries assessment method, which is 410 particularly suitable and appropriate for the differentiation and grading of incipient 411 enamel caries development, allowing to verify even minor differences in the efficacy 412 of caries-preventive measures. As described before, repeated examiner calibration assured that the assessment of the primary study outcome was based on a sound 420 foundation. Furthermore, all examiners were blinded to the dentifrice allocation of the 421 study subjects throughout the course of the study to avoid any possible examiner 422 bias. 423
424

Study population 425
The assessed study patients, wearing fixed orthodontic appliances, were without 426 doubt caries-active, documented by the considerable increase in enamel caries 427 lesions during the 168 days observation period, which was comparable in its 428 magnitude to observations made by other clinical trials [18, 29] . Due to the inevitable 429 lack of a negative control group for ethical reasons, it is however very difficult to 430 assess the true extent of caries prevention provided by the regular use of both 431 dentifrices to the study participants. It may be argued, that in the chosen setting of 432 caries-active orthodontic patients overly acidic conditions beyond the remineralizing 433 capacities of fluorides and hydroxyapatite particles might have rendered a 434 meaningful non-inferiority analysis impossible. We cannot share, however, this 435 assumption for the following reasons: In a more recent multicenter caries trial by 436 Sonesson et al. (2014) , assessing a comparable cohort of 424 adolescent patients 437 age 12-16 subjected to orthodontic therapy with fixed appliances, the regular use of a 438 highly concentrated 5000 ppm fluoride dentifrice was accompanied by a significantly 439 lower incidence of white spot enamel lesions when compared to the regular use of a 440 standard 1450 ppm fluoride control dentifrice [30] . While this suggests, that 1450 441 ppm may not be the optimal fluoride concentration for a dentifrice to be used in 442 caries-active orthodontic patients, it evidently contradicts the assumption, that in 443 these patients the caries-preventive efficacy of fluoride is completely blocked by 444 overly acidic conditions. On the contrary, Sonesson unblinded PP data set however revealed, that the actual difference between both 477 experimental groups was 6.2% in favour of the HAP test dentifrice with an exact 478 upper one-sided 95% confidence limit of 8.3%, i.e. substantially lower than the preset 479 non-inferiority margin of Δ = 20%. 480
Secondary Outcomes 481
The data for the secondary outcomes Plaque Index (PlI) and Gingival Index (GI) 482 furthermore confirmed the findings of preceding studies, reporting a significant 483 increase of gingival inflammation and bacterial plaque mass after the onset of 484 orthodontic therapy with fixed appliances [18, 29] . Differences between both 485 experimental groups regarding the recorded PlI and GI data could not be verified 486 statistically for any of the evaluated time points, which is also in good agreement with 487 the results of a previous trial comparing the plaque-and gingivitis-reducing properties 488 of a fluoride-free HAP test dentifrice and a fluoridated AmF/SnF control in a study 489 cohort of periodontitis patients [11] . 490
Outlook 491
While the safety of fluoride-based caries prevention has been firmly established by 492 numerous studies [21], dosage and toxicity aspects have always to be considered. 493
This particularly limits the clinical feasibility of the aforementioned increase in fluoride 494 dosing in high caries-risk infants and children up to an age of 8 due to the 495 asscociated risk for the development of dental fluorosis. Although not verified by 496 clinical studies so far , increasing the dosing or application frequency of HAP 497 toothpaste might also have a beneficial impact on clinical outcome in highly caries 498 active subjects because HAP is a potent buffer, able to neutralize organic acids in a 499 dose-dependent manner, By contrast to fluorides, increasing the applied dosage of 500 HAP particles is virtually free of any toxicity issues even in infants and children, as 501 HAP is the major mineral phase of all hard tissues within the human body [6] . 502 503
Conclusions 504
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